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August 3, 2010:525–30CS) during and immediately after the intracoronary injection of
ontrast media.
We report here the initial experience with a system developed
or the aspiration of contrast media from the CS during coronary
ngiography and intervention (CINCOR Contrast Removal System,
sprey Medical, St. Paul, Minnesota). The primary aim of the study
as to evaluate the safety and efficacy of this approach, and second-
rily we examined its ability to limit the decline in renal function after
ontrast exposure. A purpose-designed 11-F CS aspiration catheter
nd CS support device were placed via a 14-F right internal jugular
ein sheath. The CS was successfully cannulated with the aspiration
atheter in 31 of 41 patients. The mean time to cannulate the CS was
1.1  9.3 min. There were no device-related serious adverse events.
ur cohort included 26 patients with an estimated glomerular
ltration rate (eGFR) of 60 ml/min that were evaluated for renal
utcomes (5 pilot-phase patients had normal renal function). In this
roup, there was no change in eGFR from baseline to 72 h
ost-procedure (41.8 2.2 ml/min to 41.1 2.3 ml/min, p 0.55)
Fig. 1). By comparison, a matched comparator cohort of 148
tandard care patients (4) receiving a similar contrast load experi-
nced a significant decrease in the eGFR from 42.7  0.8 ml/min
o 40.1  0.9 ml/min (p  0.001) at 48 h. There was a greater net
ecrease in the eGFR in the comparator group: 2.5  0.5
l/min versus0.7 1.2 ml/min, p 0.05. The average amount
f blood collected by CS aspiration was 169 15 ml per patient, and
his resulted in a clinically small but statistically significant decrease in
emoglobin from 12.3  0.2 g/dl to 11.7  0.2 g/dl (p  0.01).
n 65 standard care patients with a baseline eGFR 40 ml/min,
he eGFR fell from 33.1 0.7 ml/min to 31.7 0.8 ml/min (p
.003), whereas in those with concomitant CS aspiration and an
GFR 40 ml/min (n  11), there was no change in the eGFR
30.7  1.6 ml/min to 31.4  1.8 ml/min, p  0.42). The
etween-group difference in the eGFR response was 1.5  0.5
l/min versus0.5 0.7 ml/min (p 0.05). In patients undergoing
S aspiration, we quantified the extent of radiographic contrast
apture. Unlike other experimental studies of CS capture, we directly
easured the concentration of iodine in the collected material using
nductively coupled plasma-optical emission spectroscopy. CS con-
rast aspiration resulted in the recapture of 32  3% of the
elivered contrast, ranging from 6% to 64%.
Taken together, the present study provides supportive evidence of
he safety and feasibility of a CS-based aspiration system for the
emoval of radiographic contrast in patients undergoing coronary
ngiography and intervention. Our data also provide a preliminary
ndication that the collection of contrast from the CS reduces systemic
xposure and, in conjunction, attenuates expected nephrotoxicity.
hese data warrant further evaluation in a large-scale randomized trial
o evaluate the capacity of CS contrast capture to reduce the risk of
ontrast-induced nephropathy and its complications.
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Letters to the Editor
istinct Patterns of
utoantibodies Against
-Protein–Coupled Receptors
n Chagas’ Cardiomyopathy
nd Megacolon
heir Potential Impact
or Early Risk Assessment
n Asymptomatic Chagas’ Patients
e demonstrated in the Journal (1) that patients with Chagas’
isease suffering from cardiomyopathy and megacolon show pos-
tivity of autoantibodies directed to the beta1-adrenoreceptor
AAB), beta2-AAB, and muscarinergic2-receptor (M2-AAB). A
ubset of nearly 35% of asymptomatic Chagas’ patients also
resented with AAB patterns indicative of either cardiomyopathy
beta1-AAB and M2-AAB) or megacolon (beta2-AAB and M2-
AB). Because the numbers of AAB positive but asymptomatic
ubjects paralleled the epidemiological data for the percentage of
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August 3, 2010:525–30atients who progress to symptomatic Chagas’ disease, we sug-
ested AAB measurement in asymptomatic Chagas’ patients for
ardiomyopathy and megacolon risk assessment.
We now present first indications supporting our concept. At a
edian 31 months (range 27 to 47 months) after the primary
atient classification, we were able to contact 36 of our primarily
symptomatic patients, of whom 15 were AAB-negative and 21
AB-positive. In the second investigation, none of the AAB-
egative patients reported clinical symptoms and had electrocar-
iographic characteristics indicative of progression to symptomatic
hagas’ disease. Among the AAB-positive patients of the primary
nvestigation, a 40-year-old woman presented with cardiomyopa-
hy diagnosed by electrocardiogram, demonstrating the progres-
ion to symptomatic chronic Chagas’ disease. In the primary study,
his woman had had the typical cardiomyopathy AAB composition
f beta1-AAB combined with M2-AAB. A second patient, a
1-year-old woman, presented with clinically diagnosed megaco-
on. This woman was burdened in the primary investigation with
2-AAB positivity and borderline positivity for beta2-AAB,
hich suggest megacolon risk.
Despite the tentative nature of the information presented here,
e hope that this first successful step in the evaluation of AAB
easurement in asymptomatic Chagas’ patients for cardiomyopa-
hy and megacolon risk assessment will further our concept and
ncourage other scientists to take part in its evaluation. However,
onsidering the time- and cost-intensive bioassay used for the
AB measurement (1), the development of cost-limited but
tandardized and more universally available enzyme-linked immu-
osorbent assays seems to be an essential prerequisite. Initiatives in
he enzyme-linked immunosorbent assay development should, in
ur view, first focus on M2-AAB. Both patients who progressed to
ymptomatic Chagas’ disease presented with M2-AAB in the
symptomatic stage. Therefore, we would like to suggest M2-AAB
s the preferential tool in the risk assessment of asymptomatic
hagas’ patients. The use of M2-AAB for risk assessment was also
een as a promising strategy by others (2). Using M2-AAB as a risk
arker would also account for the function of M2-AAB in driving
he alterations in the autonomic nerve system (3,4) that have
requently been discussed in the pathogenesis of Chagas’ heart and
astrointestinal disease.
ilvia Gilka Muñoz Saravia, PhD
nnekathrin Haberland, PhD
abine Bartel, PhD
aul Araujo, MD
regorio Valda, MD
iana Duchen, MS
van Diaz Ramirez, MD
drian Constantin Borges, MD, PhD
erd Wallukat, PhD
Ingolf Schimke, PhD
Medizinische Klinik für Kardiologie und Angiologie
CM, Charité
niversitätsmedizin Berlin
erlin 10117
ermany
-mail: ingolf.schimke@charite.dedoi:10.1016/j.jacc.2010.02.057EFERENCES
. Wallukat G, Munoz Saravia GS, Haberland A, et al. Distinct patterns
of autoantibodies against G-protein–coupled receptors in Chagas’
cardiomyopathy and megacolon: their potential impact for early risk
assessment in asymptomatic Chagas’ patients. J Am Coll Cardiol
2010;55:463–8.
. Goin JC, Leiros CP, Borda E, Sterin-Borda L. Interaction of human
chagasic IgG with the second extracellular loop of the human musca-
rinergic acetylcholine receptor: functional and pathological implications.
FASEB J 1997;11:77–83.
. Goin JC, Borda ES, Auger S, Storino R, Sterin-Borda L. Cardiac M(2)
muscarinic cholinoceptor activation by human chagasic autoantibodies:
association with bradycardia. Heart 1999:82:273–8.
. Sterin-Borda L, Goin JC, Bilder CR, Iantorno G, Hernando AC,
Borda E. Interaction of human chagasic IgG with human colon
muscarinic acetylcholine receptor: molecular and functional evidence.
Gut 2001;49:699–705.
uantity and Quality
n Medical Research
e read with interest the papers by Kaul et al. (1) and Stone et al.
2), published in a recent issue of the Journal. Both highlight
ividly the all too commonly found errors and limitations in
urrent medical literature. While the causes of such a state of affairs
re multiple, we believe the sheer volume of scientific papers
ublished nowadays is a major contributor.
To illustrate this point, a PubMed listings search using the
riteria “human, randomized controlled trial” reveals an astounding
rowth in the number of studies published in each 10-year strata,
tarting February 4, 1950: 1950 to 1960, no items found; 1960 to
970, 1,076 studies found; 1970 to 1980, 9,622 studies; 1980
o 1990, 36,066 studies; 1990 to 2000, 91,194 studies; and 2000 to
010, 136,109 studies found. In the past year alone, 11,276 such
apers were found using PubMed.
While such a rate of growth may be partly due to widespread use
f standardized methodology and the establishment of a worldwide
cientific community, less exalted factors such as industry pressures
3) and the “publish or perish” drive (4) may also be at play. It is,
herefore, difficult to argue that each or even most of these studies
ill be sound in their conceptual development, performance,
nalysis, and interpretation.
In truth, the scientific enterprise has in many ways become the
cientific industry, and the challenges we now face transcend
echnical or methodological limitations. Rather than quantity, we
ust now focus on quality and its indispensable antecedents,
ompetence and integrity.
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